Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.


CSE:BUX - Post by User

Bullboard Posts
Post by RealScientiston Dec 02, 2016 2:07pm
173 Views
Post# 25547795

From the November progress report

From the November progress report"The management team presented to a promising government agency that is currently conducting due diligence for an equity stake. In addition the scientific team has been in discussions with federal government officials who are reviewing BioMark’s activities that can qualify for funding in yearly 2017. All other discussions reported in the previous monthly progress are ongoing. The company is in continual communication with The Metabolomics Innovation Centre (TMIC) development team as both groups are anticipating early results of the specific signatures for breast cancer which if successful could increase its diagnostic assay pipeline. The company anticipates an update status report from its regulatory group on its current submission to Health Canada and whether there are other follow up studies needed to further establish a more substantive submission. The update is anticipated in a few weeks."

Looking like there is promising developments going on behind the scenes. News coming!
Bullboard Posts